Insider · CIK 0001905248

Espinoza Octavio

Reports to the SEC for 1 company · JUPITER, FL

sec.gov

Transactions

Companies

Filings

CIK

0001905248

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+16.2K sh	$52.84	+$855K	43,875
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,074 sh	$70.04	+$145K	45,949
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,869 sh	$55.75	+$160K	48,818
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,171 sh	$57.22	+$410K	55,989
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,348 sh	$68.74	+$230K	59,337
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−31.6K sh	$292.06	−$9.24M	27,696
2026-08-12	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,869 sh	—	—	0
2026-08-12	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,171 sh	—	—	0
2026-08-12	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−16.2K sh	—	—	0
2026-08-12	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,348 sh	—	—	0
2026-08-12	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,074 sh	—	—	0
2026-06-30	LGNDLIGAND PHARMACEUTICALS INCJ Other	Chief Financial Officer	JOther	+17 sh	$160.71	+$2,732.062	27,696
2026-05-27	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+764 sh	$63.62	+$48.6K	26,707
2026-05-27	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+972 sh	$52.84	+$51.4K	27,679
2026-05-27	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−972 sh	—	—	0
2026-05-27	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−764 sh	—	—	17,407
2026-03-11	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,405 sh	$92.65	+$223K	24,067
2026-03-11	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−3,057 sh	$225.00	−$688K	21,010
2026-03-11	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,405 sh	—	—	0
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,607 sh	$58.49	+$94K	34,619
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+466 sh	$80.72	+$37.6K	35,085
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−699 sh	$198.71	−$139K	34,386
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−53 sh	$200.08	−$10.6K	34,333
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−698 sh	$201.09	−$140K	33,635
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−950 sh	$201.73	−$192K	32,685
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−697 sh	$202.79	−$141K	31,988
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−668 sh	$203.63	−$136K	31,320
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−743 sh	$204.74	−$152K	30,577
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−1,457 sh	$205.79	−$300K	29,120
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−1,588 sh	$206.89	−$329K	27,532
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−2,457 sh	$207.91	−$511K	25,075
2026-03-04	LGNDLIGAND PHARMACEUTICALS INCS Sale	Chief Financial Officer	SSale	−3,413 sh	$208.80	−$713K	21,662
2026-03-04	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,607 sh	—	—	0
2026-03-04	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−466 sh	—	—	0
2026-03-02	LGNDLIGAND PHARMACEUTICALS INCA Award	Chief Financial Officer	AAward	+4,933 sh	—	—	37,945
2026-03-02	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+23.5K sh	—	—	23,527
2026-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Chief Financial Officer	FTax Payment	−1,026 sh	$183.83	−$189K	35,505
2026-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Chief Financial Officer	FTax Payment	−1,223 sh	$183.83	−$225K	34,282
2026-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Chief Financial Officer	FTax Payment	−1,270 sh	$183.83	−$233K	33,012
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCA Award	Chief Financial Officer	AAward	+7,390 sh	—	—	35,965
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Chief Financial Officer	FTax Payment	−3,761 sh	$183.83	−$691K	32,204
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCA Award	Chief Financial Officer	AAward	+8,810 sh	—	—	41,014
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Chief Financial Officer	FTax Payment	−4,483 sh	$183.83	−$824K	36,531
2025-12-31	LGNDLIGAND PHARMACEUTICALS INCJ Other	Chief Financial Officer	JOther	+8 sh	$95.68	+$765.408	28,575
2025-12-16	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,194 sh	$52.84	+$63.1K	27,380
2025-12-16	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+69 sh	$57.22	+$3,948.18	27,449
2025-12-16	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+285 sh	$63.62	+$18.1K	27,734
2025-12-16	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+652 sh	$92.65	+$60.4K	28,386
2025-12-16	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+181 sh	$103.42	+$18.7K	28,567
2025-12-16	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,194 sh	—	—	972

Recent filings

Accepted (ET)
Aug 144
Espinoza Octavio0002001011-26-000115
SEC(opens sec.gov)
Jul 64
Espinoza Octavio0002001011-26-000107
SEC(opens sec.gov)
May 284
Espinoza Octavio0002001011-26-000071
SEC(opens sec.gov)
Mar 274
Espinoza Octavio0002001011-26-000035
SEC(opens sec.gov)
Mar 134
Espinoza Octavio0002001011-26-000026
SEC(opens sec.gov)

Companies

LIGAND PHARMACEUTICALS INCChief Financial OfficerLGND

Address

555 HERITAGE DRIVE SUITE 200

JUPITER, FL, 33458